Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BMN NASDAQ:CRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMNBlackrock 2037 Municipal Target Term Trust$24.53$24.54$23.04▼$26.14N/AN/A13,591 shs7,922 shsCRTXCortexyme$1.89+3.3%$1.31$1.78▼$40.66$56.99M1.4620,672 shs160,022 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMNBlackrock 2037 Municipal Target Term Trust+0.10%-1.49%-1.39%+3.37%-1.21%CRTXCortexyme+5.78%+2.81%+34.56%+84.76%+140.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMNBlackrock 2037 Municipal Target Term TrustN/AN/AN/AN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMNBlackrock 2037 Municipal Target Term Trust 0.00N/AN/AN/ACRTXCortexyme 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMNBlackrock 2037 Municipal Target Term Trust$4.16MN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMNBlackrock 2037 Municipal Target Term TrustN/AN/A0.00∞N/AN/AN/AN/AN/ACRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMNBlackrock 2037 Municipal Target Term Trust$0.753.06%N/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/ALatest CRTX, SML, BMN, and PXC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/3/2025BMNBlackrock 2037 Municipal Target Term Trustmonthly$0.09384.5%7/15/20257/15/20258/1/20256/4/2025BMNBlackrock 2037 Municipal Target Term Trustmonthly$0.09384.6%6/13/20256/13/20257/1/20255/5/2025BMNBlackrock 2037 Municipal Target Term Trustmonthly$0.09384.7%5/15/20255/15/20256/2/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMNBlackrock 2037 Municipal Target Term TrustN/AN/AN/ACRTXCortexymeN/A9.929.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMNBlackrock 2037 Municipal Target Term TrustN/ACRTXCortexyme63.18%Insider OwnershipCompanyInsider OwnershipBMNBlackrock 2037 Municipal Target Term TrustN/ACRTXCortexyme27.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMNBlackrock 2037 Municipal Target Term TrustN/AN/AN/AN/ACRTXCortexyme5530.15 million21.74 millionNot OptionableCRTX, SML, BMN, and PXC HeadlinesRecent News About These CompaniesCortexyme (NASDAQ:CRTX) Stock Price Crosses Above 200-Day Moving Average - Here's WhyJuly 16 at 4:51 AM | marketbeat.comLilly files Alzheimer's drug donanemab as Cortexyme rival fails trialJanuary 26, 2025 | pharmaphorum.comPCrism Therapeutics Corp (CRTX)August 6, 2024 | fidelity.co.ukFCrism Thera Regulatory NewsAugust 4, 2024 | lse.co.ukAll the rumors are true: Syneos snapped up for $7.1B - FierceBiotechMay 12, 2023 | news.google.comNSiemens profits plummet 81% amid exit from cardiology robotics - FierceBiotechMay 11, 2023 | news.google.comNADC implements 'lower risk' R&D strategy with 17% layoffs ... - FierceBiotechMay 9, 2023 | news.google.comNFibroGen snags sole ADC asset from small biotech for $280M in ... - FierceBiotechMay 9, 2023 | news.google.comNIntuitive Surgical collects new prostate procedure clearances for its ... - FierceBiotechApril 28, 2023 | news.google.comNAntiva bags $53M in rare series E to finance quest for pivotal HPV ... - FierceBiotechApril 27, 2023 | news.google.comNAlzheimer's Disease Market in 7MM is expected to witness a major ... - Digital JournalApril 24, 2023 | news.google.comNParkinson's Disease Clinical Trials and Therapies 2023: Latest ... - Digital JournalApril 19, 2023 | news.google.comNAACR: Adela's multi-cancer blood test shows promise in detecting ... - FierceBiotechApril 18, 2023 | news.google.comNAACR: Kinnate ends cancer data wait but fails to captivate investors - FierceBiotechApril 18, 2023 | news.google.comNWith skin in the game, Satsuma's partner offers buyout to get ... - FierceBiotechApril 18, 2023 | news.google.comNCognito taps former BrainStorm president as medical chief - FierceBiotechApril 18, 2023 | news.google.comNTalaris lays off 95% of workforce after fruitless deal hunt - FierceBiotechApril 17, 2023 | news.google.comNBausch + Lomb exec to depart—Chutes & Ladders - FierceBiotechApril 14, 2023 | news.google.comNAKITA trial bites Guard as weak data force early end to phase 2 ... - FierceBiotechApril 14, 2023 | news.google.comNBioVentrix lassos $48.5M to take its ventricle-reshaping heart failure ... - FierceBiotechApril 14, 2023 | news.google.comNProthena teams with Walgreens to accelerate Alzheimer's trial - FierceBiotechApril 13, 2023 | news.google.comNMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideBy Gabriel Osorio-Mazilli | June 25, 2025View ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideThis ASML Dip Could Be Gone Before You Know It—Don’t Miss OutBy Thomas Hughes | July 16, 2025View This ASML Dip Could Be Gone Before You Know It—Don’t Miss OutAI Chip Arms Race: 3 Must-Watch Equipment StocksBy Chris Markoch | July 10, 2025View AI Chip Arms Race: 3 Must-Watch Equipment StocksCRTX, SML, BMN, and PXC Company DescriptionsBlackrock 2037 Municipal Target Term Trust NYSE:BMN$24.53 0.00 (0.00%) Closing price 07/18/2025 03:16 PM EasternExtended Trading$24.53 0.00 (0.00%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blackrock 2037 Municipal Target Term Trust is an close-ended fixed income mutual fund launched by Blackrock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in fixed income markets. The fund primarily invests in n investment grade municipal securities that are rated BBB- or above by S&P and Fitch or Baa3 or above by Moody's. Blackrock 2037 Municipal Target Term Trust is domiciled in the United States.Cortexyme NASDAQ:CRTX$1.89 +0.06 (+3.28%) As of 07/18/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
